文献速递治疗药物监测与药物基因组学肝肾功能剂量调整药物不良反应与药物警戒

12种酪氨酸激酶抑制剂的靶标达成率及药代动力学相关临床生化参数

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.
PubMed 文献 · Clin Pharmacokinet · 2026-09-04

该单中心回顾性研究纳入2020年1月至2024年8月接受12种酪氨酸激酶抑制剂(TKI)治疗的309例癌症患者,共1237次TDM浓度。多数TKI靶标达成率不理想,且肾、肝、血液学参数与TKI浓度相关,支持TDM指导的个体化给药。

要点

  • 多数TKI靶标达成率不理想,支持用TDM指导剂量优化。
  • 肾小球滤过率与阿来替尼、伊马替尼、舒尼替尼浓度相关。
  • 碱性磷酸酶、胆红素、γ-谷氨酰转移酶及血液学参数与部分TKI浓度相关。

核心结论

  • 多数TKI靶标达成率不理想,支持TDM指导的优化和个体化给药。
  • TKI暴露与肾、肝、血液学参数的相关性支持个体化治疗策略。

研究设计与样本

  • 单中心回顾性研究,纳入2020年1月至2024年8月接受TKI治疗的癌症患者。
  • 共纳入309例患者的1237次TKI浓度,采用单变量和多变量线性混合模型分析。

主要发现

  • 靶标达成率:阿来替尼74.6%,博舒替尼70%,伊马替尼按适应症49.9-61.9%,尼洛替尼88.9%,帕唑帕尼50%,普纳替尼50%,瑞戈非尼89.5%,舒尼替尼26.6%。
  • 伊布替尼、仑伐替尼和曲美替尼数据过少未正式评估;达沙替尼按适应症和参数(Cmax或Cmin)为40-87.5%。
  • 肾小球滤过率与阿来替尼、伊马替尼和舒尼替尼浓度相关。
  • 碱性磷酸酶、胆红素和γ-谷氨酰转移酶与阿来替尼相关,碱性磷酸酶与伊马替尼相关。
  • 白蛋白和血小板与伊马替尼相关,血小板与帕唑帕尼相关,中性粒细胞绝对计数与普纳替尼相关,血细胞比容与瑞戈非尼相关。

临床怎么用

  • 对多数TKI可考虑TDM指导的剂量优化和个体化给药。
  • 关注肾功能、肝功能及血液学参数对TKI暴露的影响,辅助个体化治疗决策。

局限性

  • 单中心回顾性设计可能限制结果的普遍性。
  • 伊布替尼、仑伐替尼和曲美替尼数据过少,未能正式评估靶标达成率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Tyrosine kinase inhibitors (TKIs) are targeted cancer therapies. However, TKIs are still limited due to their high inter-individual variability. This study evaluated target attainment using therapeutic drug monitoring (TDM) data from 12 TKIs, and investigated biochemical and patient-related characteristics influencing TKI pharmacokinetics (PK) METHODS: This single-centre retrospective study included cancer patients treated with TKIs between January 2020 and August 2024. Demographic, clinical, and biochemical data were extracted from electronic health records. Univariate and multivariate linear mixed models were used to identify factors associated with TKI PK. RESULTS: A total of 1237 TKI concentrations from 309 patients were included. Target attainment percentages were: 74.6% for alectinib; 70% for bosutinib; 49.9-61.9% for imatinib depending on the indication; 88.9% for nilotinib; 50% for pazopanib; 50% for ponatinib; 89.5% for regorafenib; 26.6% for sunitinib; ibrutinib, lenvatinib and trametinib had too few data for formal assessment; 40-87.5% for dasatinib, depending on indication and parameter (Cmax or Cmin). A mixed linear model analysis identified key parameters correlated with TKI concentrations. Glomerular filtration rate was correlated with alectinib, imatinib, and sunitinib. Alkaline phosphatase (ALP), bilirubin, and Gamma-GT correlated with alectinib and ALP with imatinib. Albumin and thrombocytes correlated with imatinib, thrombocytes with pazopanib, absolute neutrophiles count (ANC) with ponatinib, and haematocrit with regorafenib. CONCLUSION: Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing. Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Shirity ZNA, Mian P, Dontje A, et al. Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors. Clin Pharmacokinet. 2026. PMID: 42696096. doi:10.1007/s40262-026-01684-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。